
Will GSK’s Seasonal Strength and Oncology Focus Drive Gains?
With an average return of +5.95% and an 86.67% winning percentage from February 3 to April 29, GSK is entering a seasonal sweet spot. Recent oncology-focused acquisitions further strengthen its growth potential.